Risperidone long-acting injection: Factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up

Journal of Psychopharmacology

Volumn 24, Issue 7, 2010, Pages 995-999

  Taylor, D ^a,b   Cornelius, V ^c  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

Bed stay; Depot; Hospital; Naturalistic; Risperidone

Indexed keywords

CLOZAPINE; RISPERIDONE;

ARTICLE; ETHNICITY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; POISSON DISTRIBUTION; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953764540     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109102611     Document Type: Article

References (13)

1. Bai, YM, Chen, TT, Wu, B., Hung, CH, Lin, WK, Hu, TM, et al. (2006) A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 39: 135-141.
2. Ezewuzie, N., Taylor, D. (2006) Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 20: 86-90.
3. Gefvert, O., Eriksson, B., Persson, P., Helldin, L., Bjorner, A., Mannaert, E., et al. (2005) Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal ConstaTM) in patients with schizophrenia. Int J Neuropsychopharmacol 8: 27-36.
4. Kane, JM, Eerdekens, M., Lindenmayer, JP, Keith, SJ, Lesem, M., Karcher, K. (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125-1132.
5. Keks, NA, Ingham, M., Khan, A., Karcher, K. (2007) Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 191: 131-139.
6. Lin, KM, Poland, RE, Nuccio, I., Matsuda, K., Hathuc, N., Su, TP, et al. (1989) A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 146: 1307-1311.
7. Nesvag, R., Hendset, M., Refsum, H., Tanum, L. (2006) Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 114: 21-26.
8. Niaz, OS, Haddad, PM (2007) Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 116: 36-46.
9. Taylor, D. (2006) Risperidone long-acting injection in practice - more questions than answers ? Acta Psychiatr Scand 114: 1-2.
10. Taylor, D., Fischetti, C., Sparshatt, A., Thomas, A., Bishara, D., Cornelius, V. (2009a) Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 120: 97-101.
11. Taylor, D., Fischetti, C., Sparshatt, A., Thomas, A., Bishara, D., Cornelius, V. (2009b) Risperidone long-acting injection: a prospective 3 year analysis of its use in clinical practice. J Clin Psychiatry 70: 196-200.
12. Taylor, DM, Young, C., Patel, MX (2006) Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 9: 685-694.
13. Young, CL, Taylor, DM (2006) Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 114: 14-20.